On this episode we are joined by Otilia Mårdh, Medical Epidemiologist at ECDC, to discuss the latest reports on sexually transmitted infections in Europe.
The laboratories participating in the QA21 EQA scheme for antimicrobial susceptibility testing of N. gonorrhoeae showed good levels of competency and capability in recovering and testing strains of unknown phenotype.
You may already know about PrEP - the pill one takes to reduce the risk of acquiring HIV. But did you know there is also PEP - the post-exposure prophylaxis - that is used after one may have been exposed to the HIV virus.
The surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in the European Union/European Economic Area (EU/EEA) is essential for detecting emerging and increasing antimicrobial resistance. Since 2009, this surveillance has been co-ordinated by the European Centre for Disease Prevention and Control (ECDC). The quality-assured data produced can be used to inform treatment guidelines.
This evidence brief summarises key issues and priorities for action in Europe and Central Asia on HIV testing. It is largely based on data collected in 2021 by the European Centre for Disease Prevention and Control (ECDC) to monitor implementation of the 2004 Dublin Declaration.
This evidence brief summarises key issues and priorities for action in Europe and Central Asia on PrEP. It is largely based on data collected between March and September 2021 by the European Centre for Disease Prevention and Control (ECDC) to monitor implementation of the 2004 Dublin Declaration.
External quality assessment (EQA) is an essential part of any laboratory-based surveillance system, allowing for the monitoring of performance and comparability of results from participating laboratories, identification of potential issues and deployment of resources and training where necessary.